Summary
Ronda Dean, co-founder and CEO of Afaxys, will retire on January 2, 2026. Christian Bloomgren, currently the Chief Commercial Officer, will become the new CEO. Afaxys, a public-benefit company focused on health care, recently received $8 million in funding to improve contraceptive access in the U.S.
Key Facts
- Ronda Dean, co-founder and CEO of Afaxys since 2008, plans to retire on January 2, 2026.
- Christian Bloomgren, currently the Chief Commercial Officer, will take over as CEO.
- Bloomgren joined Afaxys in January 2024 and has prior experience in the life sciences industry and commercial leadership roles.
- Afaxys is a public-benefit company that helps over 6,700 health care sites with group purchasing and contraceptive products.
- The company received $8 million in funding to develop a new contraceptive product aimed at marginalized communities in the U.S.
- Dean will continue on as an executive advisor after her retirement.
- Afaxys will seek a new chief commercial officer after Bloomgren transitions to CEO.
